These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 22836345)

  • 1. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
    J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas?
    Hentschel M; Rottenburger C; Boedeker CC; Neumann HP; Brink I
    Clin Nucl Med; 2012 Feb; 37(2):e24-9. PubMed ID: 22228360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma.
    Timmers HJ; Hadi M; Carrasquillo JA; Chen CC; Martiniova L; Whatley M; Ling A; Eisenhofer G; Adams KT; Pacak K
    J Nucl Med; 2007 Oct; 48(10):1599-606. PubMed ID: 17873132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes.
    Marzola MC; Chondrogiannis S; Grassetto G; Rampin L; Maffione AM; Ferretti A; Opocher G; Schiavi F; Colletti PM; Rubello D
    Clin Nucl Med; 2014 Jan; 39(1):e53-8. PubMed ID: 23856824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma.
    Puar T; van Berkel A; Gotthardt M; Havekes B; Hermus AR; Lenders JW; van Marken Lichtenbelt WD; Xu Y; Brans B; Timmers HJ
    J Clin Endocrinol Metab; 2016 Jan; 101(1):224-32. PubMed ID: 26574955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
    Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of 18F-DOPA PET/CT in diagnosis and follow-up of adrenal and extra-adrenal paragangliomas.
    Bacca A; Chiacchio S; Zampa V; Carrara D; Duce V; Congregati C; Simi P; Taddei S; Materazzi G; Volterrani D; Mariani G; Bernini G
    Clin Nucl Med; 2014 Jan; 39(1):14-20. PubMed ID: 24300347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-head comparison between [
    He Q; Zhang Z; Zhang L; Zhang B; Long Y; Zhang Y; Liao Z; Zha Z; Zhang X
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1989-2001. PubMed ID: 38300262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (18)F-DOPA PET/CT and MRI: description of 12 histologically-verified pheochromocytomas.
    Magnaldi S; Mayerhoefer ME; Khameneh A; Schuetz M; Javor D; Mitterhauser M; Dudczak R; Hacker M; Karanikas G
    Anticancer Res; 2014 Feb; 34(2):791-5. PubMed ID: 24511014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Subtyping of Pheochromocytoma and Paraganglioma by
    van Berkel A; Vriens D; Visser EP; Janssen MJR; Gotthardt M; Hermus ARMM; Geus-Oei LF; Timmers HJLM
    J Nucl Med; 2019 Jun; 60(6):745-751. PubMed ID: 30413658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.
    Blanchet EM; Taieb D; Millo C; Martucci V; Chen CC; Merino M; Herscovitch P; Pacak K
    J Nucl Med; 2015 Dec; 56(12):1849-54. PubMed ID: 26359261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
    Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes.
    Gill AJ; Benn DE; Chou A; Clarkson A; Muljono A; Meyer-Rochow GY; Richardson AL; Sidhu SB; Robinson BG; Clifton-Bligh RJ
    Hum Pathol; 2010 Jun; 41(6):805-14. PubMed ID: 20236688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.